Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 2/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | EFNA1 | P20827 | 1/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 1/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 1/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 1/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 1/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 1/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | VDR | P11473 | 4/20 | 0.74 |
| ▸ | CASP7 | P55210 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ursocholanic Acid SCHEMBL19313776 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL190519 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL16084677 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL13811793 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL25023120 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL1688735 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL25023044 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL5556804 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL25021694 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL22871921 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130042671-A1 | PROGNOSTIC METHOD | NORGINE BV (NL) | 2013-02-21 | — | — | US | claimed |
| US-20090286277-A1 | PROGNOSTIC METHOD | NORGINE BV (NL) | 2009-11-19 | — | — | US | claimed |
| US-20050239712-A1 | Pharmaceutically active compound | MILLS CHARLES O | 2005-10-27 | — | — | US | claimed |
| EP-1301212-A1 | PHARMACEUTICALLY ACTIVE COMPOUND | Norgine Europe BV (NL) | 2003-04-16 | — | — | EP | claimed |
| EP-1003458-B1 | LIVER FUNCTION TEST | NORGINE EUROPE BV (NL) | 2002-10-23 | — | — | EP | claimed |
| WO-2002007771-A1 | PHARMACEUTICALLY ACTIVE COMPOUND | NORGINE EUROPE BV (NL) | 2002-01-31 | — | — | WO | claimed |
| EP-1003458-A2 | LIVER FUNCTION TEST | Norgine Limited (GB) | 2000-05-31 | — | — | EP | claimed |
| US-6030841-A | PROCESSING SERIES OF BLOOD SAMPLES OBTAINED AT TIMED INTERVALS AFTER INTRAVENOUS INJECTION OF COLORED/FLUORESCENT BILE ACID DERIVATIVE TO OBTAIN PLASMA, MEASURING COLOR OR FLUORESCENCE, FITTING TO PLASMA ELIMINATION CURVE, COMPARING | NORGINE LIMITED (GB) | 2000-02-29 | — | — | US | claimed |
| WO-1999007325-A1 | LIVER FUNCTION TEST | NORGINE LIMITED (GB) | 1999-02-18 | — | — | WO | claimed |
| WO-2025108545-A1 | DELIVERY OF NUCLEOTIDES FROM INJECTABLE BIOMATERIAL | DANMARKS TEKNISKE UNIVERSITET (DK) | 2025-05-30 | — | — | WO | disclosed |
| EP-4529453-A1 | NUCLEOTIDE DELIVERY FROM INJECTABLE HYDROPHOBIC BIOMATERIAL | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-4529468-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| WO-2023227548-A1 | NUCLEOTIDE DELIVERY FROM INJECTABLE HYDROPHOBIC BIOMATERIAL | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227517-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-30 | — | — | WO | disclosed |
| US-6030841-A | PROCESSING SERIES OF BLOOD SAMPLES OBTAINED AT TIMED INTERVALS AFTER INTRAVENOUS INJECTION OF COLORED/FLUORESCENT BILE ACID DERIVATIVE TO OBTAIN PLASMA, MEASURING COLOR OR FLUORESCENCE, FITTING TO PLASMA ELIMINATION CURVE, COMPARING | NORGINE LIMITED (GB) | 2000-02-29 | — | — | US | disclosed |
| WO-1999007325-A1 | LIVER FUNCTION TEST | NORGINE LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| EP-0844890-A1 | THE USE OF BILE ACID DERIVATIVES | THE UNIVERSITY OF BIRMINGHAM (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997006829-A1 | THE USE OF BILE ACID DERIVATIVES | THE UNIVERSITY OF BIRMINGHAM (GB) | 1997-02-27 | — | — | WO | disclosed |
| EP-0296622-A2 | Derivatives of poly(diallyl-methylamine) and their use as cholesterol-lowering agents | HERCULES INCORPORATED (US) | 1988-12-28 | — | — | EP | disclosed |
| US-4759923-A | Orally administering to the animal therapeutical amount of quaternized crosslinked polydiallylmethylamine | HERCULES INCORPORATED (US) | 1988-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239712-A1 | Pharmaceutically active compound | CYP7A1, CYP8B1, CYP46A1 | GPBAR1 68/4885EPHA2 2277/4885HSD17B10 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.